Evidence map›Paper›PMID 41438429›Full record

ReviewInternational journal of nanomedicine2025

Nanozymes Targeting Redox Imbalance: A Novel Weapon for Immunomodulation and Organ Protection in Sepsis.

Junlong Gao, Xiaobo Pang, Yulan Li

Abstract readReview
In one paragraph

Review in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Junlong GaoThe First School of Clinical Medicine, Lanzhou University, Lanzhou, Gansu, People's Republic of China.
Xiaobo PangState Key Laboratory of Applied Organic Chemistry (SKLAOC), College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, Gansu, People's Republic of China.
Yulan LiThe First School of Clinical Medicine, Lanzhou University, Lanzhou, Gansu, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sepsis remains a major challenge in critical care, with high mortality despite ongoing improvements in treatment. The early uncontrolled burst of reactive oxygen and nitrogen species (RONS) and cytokine storms form a vicious cycle, ultimately leading to multiple organ dysfunction syndrome (MODS). The absence of effective therapies to interrupt this process is likely a key reason for poor outcomes. In recent years, the emergence of nanozymes has represented a transformative breakthrough in addressing this challenge. With strong antioxidant capacity, high stability, and low cost, nanozymes surpass conventional antioxidants and offer a promising therapeutic strategy for sepsis, especially through effective redox regulation. Nanozymes not only efficiently scavenge diverse RONS but also inhibit hyperactivated inflammatory pathways, thereby breaking the fatal vicious cycle between oxidative stress and cytokine storms. This provides a novel approach for immunomodulation and organ protection in sepsis. This review summarizes the key role of redox imbalance in sepsis progression and the therapeutic potential of nanozymes targeting redox imbalance, discusses their in vivo metabolic distribution and biosafety, and outlines prospects for future clinical translation and development. The objective is to provide insights that facilitate the development of innovative therapies targeting the RONS-inflammation axis in sepsis.

Indexed as

AntioxidantsCytokine Release SyndromeImmunomodulating AgentsMultiple Organ FailureNanoparticlesSepsisAnimalsHumansImmune ToleranceImmunomodulationOxidation-ReductionOxidative StressReactive Nitrogen SpeciesAntioxidantsImmunomodulating AgentsReactive Nitrogen Speciescytokine stormimmunosuppressionnanozymesorgan protectionredox imbalancesepsis

Identifiers

PMID41438429
PMCPMC12720921

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.